SkinBioTherapeutics plc (AIM: SBTX), shares fell around 30% after the skin health-focused life sciences company announced the resignation of its chief executive officer, Stuart Ashman.
hVIVO Shares Climb 63% Over Two Days Following ILiAD Biotechnologies Series B Funding Round
Shares in hVIVO PLC have advanced 63% over two trading sessions, rising to 9.98p (day high 10.20p), following news that ILiAD Biotechnologies has secured $ 115 million in Series B
Positive dog gene therapy data lifts Genflow shares 15%
Genflow Biosciences PLC (LON: GENF) has reported encouraging preliminary interim results from its SLAB clinical trial assessing its SIRT6 gene therapy in aged dogs.
Avacta Therapeutics (AIM: AVCT) Appoints Francis Wilson as Chief Scientific Officer
Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer.
Avacta Therapeutics (AIM: AVCT) Faridoxorubicin Program Clinical Updates
Avacta announces two key clinical updates to its faridoxorubicin program Cardiac dosing limit removed and path forward to dose selection identified
City Brokers See Potential Turning Point for hVIVO
hVIVO PLC reported annual revenue of £46.7 million, which met market expectations, prompting City brokers to evaluate whether the clinical research organisation has begun to reverse its fortunes after a
hVIVO plc (AIM: HVO) Trading Update
FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
Poolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
hVIVO plc (AIM: HVO) Notice of Trading Update
Notice of Trading Update
GENinCode plc (AIM: GENI) shares plunge 40% after deeply discounted placing
GENinCode plc (AIM: GENI) has conditionally raised £3.9m in gross proceeds through the issue of 388,145,000 new ordinary shares at 1p each, representing a 47.4pc discount to the closing middle
Avacta Therapeutics (AIM: AVCT) FDA Clearance of IND Application for AVA6103
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026
OptiBiotix Health secures large order, sees record early 2026 demand
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes,